Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

This is the authors' abstract. We don't add key points for this paper.

The ibrutinib-rituximab regimen resulted in progression-free survival and overall survival that were superior to those with a standard chemoimmunotherapy regimen among patients 70 years of age or younger with previously untreated CLL. (Funded by the National Cancer Institute and Pharmacyclics; E1912 ClinicalTrials.gov number, NCT02048813.).